ALL COMPANIES

YTX-7739 is a small molecule that acts as an alpha synuclein pathology inhibitor, potentially inhibiting the aggregation of alpha-synuclein and...

This is an antisense therapy that aims for alpha synuclein reduction by targeting the production of alpha-synuclein at the genetic...

ACI-7104 is a vaccine that functions as an alpha synuclein pathology inhibitor, helping the immune system recognize and clear pathological...

ATH-434 is a small molecule that inhibits alpha synuclein pathology, designed to bind to pathological alpha-synuclein and prevent its toxic...

Lu-AF82422 is an antibody targeting alpha synuclein pathology, with the goal of neutralizing toxic alpha-synuclein aggregates.

This therapeutic is an antibody that works as an aSyn pathology inhibitor, aiming to block the propagation of toxic alpha-synuclein...

Minzasolmin (UCB-0599/DLX-313) is a small molecule that acts as analpha synuclein pathology inhibitor, potentially reducing the accumulation of toxic alpha-synuclein.

This is the same antibody as listed above, prasinezumab, used for inhibiting alpha synuclein pathology.

Buntanetap (ANVS-401) is a small molecule aimed at alpha synuclein reduction, designed to lower the production or aggregation of alpha-synuclein,...